Literature DB >> 12074772

Nonfunctioning islet cell carcinoma of the pancreas.

Steven Neeleman1, Michael J Demeure.   

Abstract

Islet cell cancers of the pancreas may follow an indolent course. Unlike adenocarcinoma of the pancreas, which is considered inoperable for cure in the presence of metastatic disease, islet cell carcinoma of the pancreas in selected cases warrants an aggressive approach toward resection. Significant palliation may be obtained from resection of primary tumors despite the presence of liver metastases. Furthermore, resection or ablation of limited, metastatic disease in the liver may be indicated. Therapeutic decisions must consider the patient's symptoms, coexisting morbidities, and the extent of the disease.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12074772     DOI： 10.1007/s11864-002-0035-y

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  10 in total

1.  Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients.

Authors:  C C Solorzano; J E Lee; P W Pisters; J N Vauthey; G D Ayers; M E Jean; R F Gagel; J A Ajani; R A Wolff; D B Evans
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

2.  Radiotherapy in the management of pancreatic islet cell tumors.

Authors:  J R Torrisi; J Treat; R Zeman; A Dritschilo
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

3.  The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors.

Authors:  C H van Eijck; S W Lamberts; L C Lemaire; H Jeekel; F T Bosman; J C Reubi; H A Bruining; E P Krenning
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

4.  Hepatic neuroendocrine metastases: does intervention alter outcomes?

Authors:  R S Chamberlain; D Canes; K T Brown; L Saltz; W Jarnagin; Y Fong; L H Blumgart
Journal:  J Am Coll Surg       Date:  2000-04       Impact factor: 6.113

5.  Management of nonfunctioning islet cell carcinomas.

Authors:  D K Bartsch; T Schilling; A Ramaswamy; B Gerdes; I Celik; H J Wagner; B Simon; M Rothmund
Journal:  World J Surg       Date:  2000-11       Impact factor: 3.352

Review 6.  Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

Authors:  Y P Le Treut; J R Delpero; B Dousset; D Cherqui; P Segol; G Mantion; L Hannoun; G Benhamou; B Launois; O Boillot; J Domergue; H Bismuth
Journal:  Ann Surg       Date:  1997-04       Impact factor: 12.969

7.  Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors.

Authors:  K A Yao; M S Talamonti; A Nemcek; P Angelos; H Chrisman; J Skarda; A B Benson; S Rao; R J Joehl
Journal:  Surgery       Date:  2001-10       Impact factor: 3.982

8.  Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach.

Authors:  Juan M Sarmiento; Florencia G Que; Clive S Grant; Geoffrey B Thompson; Michael B Farnell; David M Nagorney
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

9.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

Review 10.  Radiotherapy for unresectable endocrine pancreatic carcinomas.

Authors:  J Tennvall; O Ljungberg; B Ahrén; A Gustavsson; L O Nillson
Journal:  Eur J Surg Oncol       Date:  1992-02       Impact factor: 4.424
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.